AKR7A2

Across TCGA pan-cancer cohorts, AKR7A2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of AKR7A2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where AKR7A2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AKR7A2 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

COAD, HNSC, and CCRCC are the cancer types where AKR7A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AKR7A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	−0.638	<.001	12	view →
HNSC	Female	All	−0.542	<.001	12	view →
CCRCC	Male	II,III,IV	−0.358	<.001	10	view →
LSCC	Male	III,IV	−0.393	<.001	9	view →
LUAD	All	III,IV	−0.272	<.001	8	view →
OV	All	All	−0.477	.003	2	view →
PDAC	All	All	+0.174	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

AKR7A2–COAD

Open the COAD breakdown →